A Toast to the Last Decade and a Very Happy 2020 from Thrombosis and Haemostasis!

We are very happy to start 2020 with our traditional January Editorial and Editor's Choice,[1] [2] [3] [4] especially as this year commemorates a special date for us. Ten years ago, Thrombosis and Haemostasis endowed itself for the first time with two Editors-in-Chief, one each for Basic and Clinical Science. We are very grateful for this fruitful collaboration and these past 10 years working with you, our authors, readers and reviewers.

Christian Weber and Gregory Y. H. Lip at a conference in Basel, 2017.

In 2019, we could once more count on around 900 submissions from you, a number that has remained stable and portrays the confidence you have in Thrombosis and Haemostasis. Our Impact factor and CiteScore have maintained a stable trend in comparison to others in the field, specifically reflected by the CiteScore Percentile in the category hematology, which matched near 90th, over the past 5 years. We continue to serve as a link journal for the European Society of Cardiology Working Groups on Thrombosis and on Atherosclerosis and Vascular Biology, as well as being the official journal of the Society of Thrombosis and Hemostasis Research (GTH), the Spanish (SETH) society on Thrombosis and Haemostasis and the Australian Vascular Biology Society (AVBS).

• References

• 1 Lip GYH, Weber C. A happy new year from a 60-year-old journal ‘Thrombosis and Haemostasis’!. Thromb Haemost 2018; 118 (01) 1-3
• 2 Lip GYH, Weber C. Thrombosis and haemostasis wishes you a happy new year ahead!. Thromb Haemost 2019; 119 (01) 1-2
• 3 Weber C, Lip GYH. Editors' choice in the 60th anniversary year of thrombosis and haemostasis: past, present and future. Thromb Haemost 2018; 118 (01) 225-227
• 4 Weber C, Lip GYH. Thrombosis and haemostasis 2018 editor's choice papers. Thromb Haemost 2019; 119 (01) 183-186
• 5 Steffens S, Weber C. Immunotherapy for atherosclerosis-novel concepts. Thromb Haemost 2019; 119 (04) 515-516
• 6 Kaltner H, Gabius H-J. Sensing glycans as biochemical messages by tissue lectins: the sugar code at work in vascular biology. Thromb Haemost 2019; 119 (04) 517-533
• 7 Gencer S, van der Vorst EPC, Aslani M, Weber C, Döring Y, Duchene J. Atypical chemokine receptors in cardiovascular disease. Thromb Haemost 2019; 119 (04) 534-541
• 8 Van Avondt K, Maegdefessel L, Soehnlein O. Therapeutic targeting of neutrophil extracellular traps in atherogenic inflammation. Thromb Haemost 2019; 119 (04) 542-552
• 9 Sinitski D, Kontos C, Krammer C, Asare Y, Kapurniotu A, Bernhagen J. Macrophage migration inhibitory factor (MIF)-based therapeutic concepts in atherosclerosis and inflammation. Thromb Haemost 2019; 119 (04) 553-566
• 10 Guillamat-Prats R, Rami M, Herzig S, Steffens S. Endocannabinoid signalling in atherosclerosis and related metabolic complications. Thromb Haemost 2019; 119 (04) 567-575
• 11 Natarelli L, Weber C. Next-generation therapeutic concepts for atherosclerosis: focus on cell specificity and noncoding RNAs. Thromb Haemost 2019; 119 (08) 1199-1201
• 12 Paloschi V, Winter H, Viola J, Soehnlein O, Maegdefessel L. Mechanistic links between non-coding RNAs and myeloid cell inflammation in atherosclerosis. Thromb Haemost 2019; 119 (08) 1205-1211
• 13 Busygina K, Denzinger V, Bernlochner I, Weber C, Lorenz R, Siess W. Btk inhibitors as first oral atherothrombosis-selective antiplatelet drugs?. Thromb Haemost 2019; 119 (08) 1212-1221
• 14 Holdt LM, Kohlmaier A, Teupser D. Long noncoding RNAs of the arterial wall as therapeutic agents and targets in atherosclerosis. Thromb Haemost 2019; 119 (08) 1222-1236
• 15 Joppich M, Weber C, Zimmer R. Using context-sensitive text mining to identify mirnas in different stages of atherosclerosis. Thromb Haemost 2019; 119 (08) 1247-1264
• 16 Eckardt V, Weber C, von Hundelshausen P. Glycans and glycan-binding proteins in atherosclerosis. Thromb Haemost 2019; 119 (08) 1265-1273
• 17 Pircher J, Engelmann B, Massberg S, Schulz C. Platelet-neutrophil crosstalk in atherothrombosis. Thromb Haemost 2019; 119 (08) 1274-1282
• 18 Verheugt FWA. Platelets: the balance between aggregation and bleeding. Thromb Haemost 2019; 19 (10) 1553
• 19 Kaikita K, Hosokawa K, Dahlen JR, Tsujita K. Total thrombus-formation analysis system (T-TAS): clinical application of quantitative analysis of thrombus formation in cardiovascular disease. Thromb Haemost 2019; 19 (10) 1554-1562
• 20 Stojkovic S, Nossent AY, Haller P. , et al. MicroRNAs as regulators and biomarkers of platelet function and activity in coronary artery disease. Thromb Haemost 2019; 19 (10) 1563-1572
• 21 Schrör K, Kristensen SD, Storey RF, Verheugt FWA. Aspirin and primary prevention in patients with diabetes-a critical evaluation of available randomized trials and meta-analyses. Thromb Haemost 2019; 19 (10) 1573-1582
• 22 Sumaya W, Geisler T, Kristensen SD, Storey RF. Dual antiplatelet or dual antithrombotic therapy for secondary prevention in high-risk patients with stable coronary artery disease?. Thromb Haemost 2019; 19 (10) 1583-1589
• 23 Geisler T, Jorbenadze R, Popov A-F. , et al. Thrombogenicity and antithrombotic strategies in structural heart interventions and nonaortic cardiac device therapy-current evidence and practice. Thromb Haemost 2019; 19 (10) 1590-1605
• 24 Esteve-Pastor MA, Roldán V, Rivera-Caravaca JM, Ramírez-Macías I, Lip GYH, Marín F. The use of biomarkers in clinical management guidelines: a critical appraisal. Thromb Haemost 2019; 119 (12) 1901-1919
• 25 Ntaios G, Lip GYH. Stroke: insights into thromboembolism treatment and prevention through the decades. Thromb Haemost 2019; 119 (05) 685-687
• 26 Fiechter M, Haider A, Bengs S. , et al. Sex differences in the association between inflammation and ischemic heart disease. Thromb Haemost 2019; 119 (09) 1471-1480
• 27 Fanikos J, Murwin D, Gruenenfelder F. , et al. Global use of idarucizumab in clinical practice: outcomes of the RE-VECTO surveillance program. Thromb Haemost 2019; 120 (02) 27-35